查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401863

2030 年瘧疾疫苗市場預測：按藥物、疫苗類型、途徑、配銷通路、最終用戶和地區進行的全球分析

Malaria Vaccine Market Forecasts to 2030 - Global Analysis By Agent (Anopheles Species, Plasmodium Vivax, Plasmodium Falciparum and Other Agents), Vaccine Type, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球瘧疾疫苗市場規模將達541億美元，預計2030年將達到3,695億美元，預測期內複合年成長率為31.6%。

瘧疾疫苗是針對蚊媒感染疾病提供保護的藥物。當被攜帶瘧疾中毒的雌性瘧蚊叮咬時，它會傳播一種稱為瘧原蟲原蟲性疾病的疾病。出汗、發燒和發冷是這種慢性疾病的症狀。給藥這些疫苗的方法有很多種，包括肌肉注射、皮下注射和皮內注射。

據世界衛生組織稱，2019年全球約有2.29億人感染瘧疾，40.9萬人死亡。瘧疾主要困擾非洲、亞洲、中南美洲等熱帶地區。

瘧疾發病率高

多年來，瘧疾一直是主要的健康問題，特別是在熱帶和亞熱帶地區。瘧疾流行是由多種因素驅動的，包括氣候變遷、蚊子和寄生蟲的抗藥性、衛生基礎設施不足以及社會經濟因素。然而，由於環境條件的變化和現有預防策略有效性的變化，盛行率有所增加。這些因素都促進了市場的成長。

缺乏醫療基礎設施

衛生基礎設施不足限制了使用衛生設施的機會，並使疫苗難以取得。在偏遠地區，沒有診所或醫院來妥善儲存和管理疫苗。由於衛生系統不足，健康教育和疫苗接種宣傳活動也受到限制。這種知識的缺乏可能會導致疫苗接種率低或對疫苗接種猶豫不決。這是阻礙市場拓展的因素。

增加研發活動

新興市場疫苗接種成本、安全性和有效性的開拓將影響市場擴張。公共和商業性研究投資影響更新、更強大的疫苗的可用性。此外，政府和國際衛生組織的支持可以對瘧疾疫苗的採用和普及產生重大影響，特別是在資源有限的環境中。這些都是影響市場擴張的變數。

藥物研發成本高

疫苗開發過程需要大量的財務投資，因為它需要嚴格的研究、臨床試驗和監管程序。高製造成本影響大規模生產和分銷的永續性。它也可能阻礙為最需要的人接種疫苗的長期努力。贊助這些配合措施的製藥公司、政府和組織面臨高昂成本的挑戰。

新冠肺炎 (COVID-19) 影響：

醫療用品（特別是預防和治療瘧疾所需的醫療用品）的生產和供應因 COVID-19 造成的全球供應鏈中斷而受到阻礙。這影響了診斷設備、抗瘧疾藥和散佈殺蟲劑的蚊帳的供應。封鎖、旅行禁令和麵對面諮詢的限制都導致瘧疾疫苗接種臨床研究中斷。這導致了測試、觀察分析和獲得監管部門批准的延遲。

預計按蚊物種部分在預測期內將是最大的

預計按蚊物種部分在預測期內將是最大的。透過接種針對瘧蚊的疫苗可以直接解決瘧疾傳播問題。透過降低蚊子傳播瘧疾感染的能力，可以顯著減緩瘧疾傳播。針對瘧疾寄生蟲本身的疫苗接種研究目前正在進行中，而針對按蚊物種的疫苗的開發將有助於此類努力。

預測期內，肌肉注射細分市場的複合年成長率最高。

預計肌肉注射領域在預測期內複合年成長率最高。對於醫療專業人員來說，肌肉注射疫苗是一個相當簡單的過程。除了正常的注射程序外，不需要專門的訓練。當肌肉注射時，某些疫苗更穩定，可以更好地保持其有效性。這對於冷藏和醫療服務不便的地區常見疾病的疫苗接種尤其重要。

佔有率最大的地區

預計北美在預測期內將佔據最大的市場佔有率。由於這種疾病的廣泛影響，世界各地正在配合措施開發和實施瘧疾疫苗接種。隨著北美大陸風險的下降，該地區不再關注全民免疫，而是更關注對瘧疾高發地區的人們進行預防。對於前往瘧疾流行地區的人來說，重要的預防措施是避免蚊蟲叮咬並使用抗瘧疾藥。

複合年成長率最高的地區：

由於瘧疾病例數量增加、人口成長以及政府控制疾病的配合措施加大，預計亞太地區在預測期內將維持最高的複合年成長率。學術機構、製藥公司和國際衛生組織正在不懈地努力開發更有效的瘧疾疫苗。也正在進行研究，重點在於針對瘧疾寄生蟲生命週期不同階段的替代疫苗接種策略，以提高功效。

免費客製化服務

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球瘧疾疫苗市場：依藥物分類

  • 介紹
  • 按蚊種
  • 間日瘧原蟲
  • 惡性瘧原蟲
  • 其他

第6章全球瘧疾疫苗市場：依疫苗類型

  • 介紹
  • 紅血球前疫苗
  • 紅血球疫苗
  • 多重抗原疫苗
  • 其他類型的疫苗

第7章全球瘧疾疫苗市場：依給藥途徑分類

  • 介紹
  • 肌肉注射
  • 皮下的
  • 皮內

第8章全球瘧疾疫苗市場：依配銷通路

  • 介紹
  • 零售藥房
  • 線上藥房
  • 醫院藥房
  • 其他配銷通路

第9章全球瘧疾疫苗市場：依最終用戶分類

  • 介紹
  • 醫院
  • 專科診所
  • 居家醫療
  • 其他最終用戶

第10章全球瘧疾疫苗市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Taj Pharmaceuticals Limited
  • Sanofi
  • Actiza Pharmaceutical Private Limited
  • Ipca Laboratories Ltd.
  • Sumaya Biotech
  • Hikma Pharmaceuticals PLC
  • Bliss GVS Pharma Ltd.
  • Amneal Pharmaceuticals LLC
  • Strides Pharma Science Limited
  • VLP Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Mylan NV
  • Zydus Cadila
  • Cipla Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Ipca Laboratories Ltd.
  • GeoVax
Product Code: SMRC24383

According to Stratistics MRC, the Global Malaria Vaccine Market is accounted for $54.1 billion in 2023 and is expected to reach $369.5 billion by 2030 growing at a CAGR of 31.6% during the forecast period. Vaccines against malaria are medicines that offer protection against the infectious sickness carried by mosquitoes. The bite of a female Anopheles mosquito carrying the malaria virus transmits the disease, sometimes referred to as plasmodium infection. Sweating, fever, and chills are signs of this chronic illness. There are a few different ways to administer these vaccines: intramuscular, subcutaneous, and intradermal injections.

According to the WHO, there were around 229 million malaria infections and 409,000 fatalities worldwide in 2019. Malaria has primarily plagued tropical areas such as Africa, Asia, Central America, and South America.

Market Dynamics:

Driver:

High Incidence of malaria

Malaria has been a significant health concern for many years, particularly in tropical and subtropical regions. Several factors contribute to the prevalence of malaria, including climate change, drug resistance in mosquitoes and parasites, inadequate healthcare infrastructure, and socioeconomic factors. However, the rise in prevalence occurs due to changing environmental conditions or shifts in the effectiveness of existing prevention strategies. These factors contribute to the growth of the market.

Restraint:

Lack of healthcare infrastructure

People find it challenging to obtain vaccines due to restricted access to healthcare facilities resulting from inadequate infrastructure for healthcare. There aren't any clinics or hospitals in remote locations that are set up to properly store and give immunizations. Inadequate healthcare systems may also result in restricted availability of health education and immunization awareness initiatives. Low vaccination uptake and vaccine hesitancy may result from this lack of knowledge. This is the element impeding the market's expansion.

Opportunity:

Increase in the number of research and development activities

Developments in vaccination cost, safety, and effectiveness have an impact on market expansion. Public and commercial research investments have an impact on the availability of more recent and potent vaccinations. Furthermore, particularly in environments with limited resources, government and international health agency support can have a major influence on the uptake and dissemination of malaria vaccinations. These are the variables affecting the market's expansion.

Threat:

High cost of medication development

The process of developing a vaccine necessitates significant financial investments due to the rigorous research, clinical trials, and regulatory procedures involved. The sustainability of mass production and distribution is impacted if the cost of manufacturing is high. Long-term efforts to get the vaccination to people who need it most could be hampered by it. Pharmaceutical firms, governments, and organizations that sponsor these initiatives have difficulties because to the exorbitant expenses.

COVID-19 Impact:

The manufacture and delivery of medical goods, especially those required for the prevention and treatment of malaria, were hampered by the worldwide interruptions in supply chains brought about by COVID-19. This impacted the supply of diagnostic instruments, antimalarial medications, and bed nets sprayed with insecticide. Lockdowns, travel bans, and limits on face-to-face encounters all caused interruptions to clinical studies for malaria vaccinations. As a result, there has been a delay in testing, findings analysis, and gaining regulatory permissions.

The anopheles species segment is expected to be the largest during the forecast period

The anopheles species segment is expected to be the largest during the forecast period. The transmission of malaria is directly addressed by vaccination against the anopheles species. It may considerably slow the transmission of malaria by lessening the mosquito's capacity to disseminate the infection. Research on vaccinations against the malaria parasite itself is ongoing, however these efforts would be aided by the development of a vaccine against the anopheles species.

The intramuscular segment is expected to have the highest CAGR during the forecast period

The intramuscular segment is expected to have the highest CAGR during the forecast period. For medical experts, administering a vaccination intramuscularly is a rather simple process. Specialized training beyond normal injection procedures is not needed. When injected intramuscularly, certain vaccinations are more stable and maintain their effectiveness more effectively. This is particularly important for vaccinations against illnesses that are common in areas without easy access to refrigeration or healthcare services.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Due of the disease's extensive effects, efforts have been made globally to develop and implement malaria vaccinations. Because of the decreased risk within the continent, the focus in this region has mostly been on preventive methods for visitors to malaria-prone regions rather than universal immunization. The key tactics for people visiting areas where malaria is endemic continue to be preventing mosquito bites and using antimalarial drugs.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to the increasing number of malarial infections, rising population and increasing government initiative for disease control. To create more potent malaria vaccines, academic institutions, pharmaceutical firms, and international health organizations have been working nonstop. In an effort to increase effectiveness, some ongoing research focuses on alternate vaccination strategies that target various phases of the malaria parasite's lifecycle.

Key players in the market:

Some of the key players in Malaria Vaccine market include Taj Pharmaceuticals Limited, Sanofi, Actiza Pharmaceutical Private Limited, Ipca Laboratories Ltd., Sumaya Biotech, Hikma Pharmaceuticals PLC, Bliss GVS Pharma Ltd., Amneal Pharmaceuticals LLC, Strides Pharma Science Limited, VLP Therapeutics, Novartis AG, Pfizer Inc., Mylan N.V., Zydus Cadila, Cipla Inc., Sun Pharmaceutical Industries Ltd., Ipca Laboratories Ltd. and GeoVax.

Key Developments:

In February 2023, Sun Pharmaceutical Industries Ltd., one of India's leading pharmaceutical companies, has announced the acquisition of a 26.09% stake in Agatsa Software Pvt. Ltd. and a 27.39% stake in Remidio Innovative Solutions Pvt. Ltd., both of which are digital health startups.

In November 2022, Novartis and Medicines for Malaria Venture (MMV) have announced plans to advance a ganaplacide/lumefantrine- solid dispersion formulation (SDF) into a Phase III clinical trial to treat individuals with acute uncomplicated malaria caused by Plasmodium falciparum.

Agents Covered:

  • Anopheles Species
  • Plasmodium Vivax
  • Plasmodium Falciparum
  • Other Agents

Vaccine Types Covered:

  • Pre-Erythrocytic Vaccine
  • Erythrocytic Vaccine
  • Multi-antigen Vaccine
  • Other Vaccine Types

Route of Administrations Covered:

  • Intramuscular
  • Subcutaneous
  • Intradermal

Distribution Channels Covered:

  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Malaria Vaccine Market, By Agent

  • 5.1 Introduction
  • 5.2 Anopheles Species
  • 5.3 Plasmodium Vivax
  • 5.4 Plasmodium Falciparum
  • 5.5 Other Agents

6 Global Malaria Vaccine Market, By Vaccine Type

  • 6.1 Introduction
  • 6.2 Pre-Erythrocytic Vaccine
  • 6.3 Erythrocytic Vaccine
  • 6.4 Multi-antigen Vaccine
  • 6.5 Other Vaccine Types

7 Global Malaria Vaccine Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intramuscular
  • 7.3 Subcutaneous
  • 7.4 Intradermal

8 Global Malaria Vaccine Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Online Pharmacy
  • 8.4 Hospital Pharmacy
  • 8.5 Other Distribution Channels

9 Global Malaria Vaccine Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Specialty Clinics
  • 9.4 Homecare
  • 9.5 Other End Users

10 Global Malaria Vaccine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Taj Pharmaceuticals Limited
  • 12.2 Sanofi
  • 12.3 Actiza Pharmaceutical Private Limited
  • 12.4 Ipca Laboratories Ltd.
  • 12.5 Sumaya Biotech
  • 12.6 Hikma Pharmaceuticals PLC
  • 12.7 Bliss GVS Pharma Ltd.
  • 12.8 Amneal Pharmaceuticals LLC
  • 12.9 Strides Pharma Science Limited
  • 12.10 VLP Therapeutics
  • 12.11 Novartis AG
  • 12.12 Pfizer Inc.
  • 12.13 Mylan N.V.
  • 12.14 Zydus Cadila
  • 12.15 Cipla Inc.
  • 12.16 Sun Pharmaceutical Industries Ltd.
  • 12.17 Ipca Laboratories Ltd.
  • 12.18 GeoVax

List of Tables

  • Table 1 Global Malaria Vaccine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 3 Global Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 4 Global Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 5 Global Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 6 Global Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 7 Global Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 8 Global Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 9 Global Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 10 Global Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 11 Global Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 12 Global Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 12 Global Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 14 Global Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 15 Global Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 16 Global Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 18 Global Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 19 Global Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 20 Global Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 21 Global Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 22 Global Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 24 Global Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 25 Global Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 26 North America Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 27 North America Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 28 North America Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 29 North America Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 30 North America Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 31 North America Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 32 North America Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 33 North America Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 34 North America Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 35 North America Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 36 North America Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 37 North America Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 38 North America Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 39 North America Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 40 North America Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 41 North America Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 42 North America Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 43 North America Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 44 North America Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 45 North America Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 46 North America Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 47 North America Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 48 North America Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 49 North America Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 50 North America Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 51 Europe Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 52 Europe Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 53 Europe Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 54 Europe Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 55 Europe Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 56 Europe Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 57 Europe Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 58 Europe Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 59 Europe Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 60 Europe Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 61 Europe Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 62 Europe Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 63 Europe Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 64 Europe Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 65 Europe Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 66 Europe Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 67 Europe Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 68 Europe Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 69 Europe Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 70 Europe Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 71 Europe Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 72 Europe Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 73 Europe Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 74 Europe Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 75 Europe Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 76 Asia Pacific Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Asia Pacific Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 78 Asia Pacific Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 79 Asia Pacific Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 80 Asia Pacific Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 81 Asia Pacific Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 82 Asia Pacific Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 83 Asia Pacific Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 84 Asia Pacific Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 85 Asia Pacific Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 86 Asia Pacific Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 87 Asia Pacific Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 88 Asia Pacific Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 89 Asia Pacific Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 90 Asia Pacific Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 91 Asia Pacific Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 92 Asia Pacific Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 93 Asia Pacific Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 94 Asia Pacific Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 95 Asia Pacific Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 96 Asia Pacific Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 97 Asia Pacific Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 98 Asia Pacific Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 99 Asia Pacific Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 100 Asia Pacific Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 South America Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 South America Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 103 South America Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 104 South America Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 105 South America Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 106 South America Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 107 South America Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 108 South America Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 109 South America Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 110 South America Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 111 South America Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 112 South America Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 113 South America Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 114 South America Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 115 South America Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 116 South America Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 117 South America Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 118 South America Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 119 South America Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 120 South America Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 121 South America Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 122 South America Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 123 South America Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 124 South America Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 125 South America Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 126 Middle East & Africa Malaria Vaccine Market Outlook, By Country (2021-2030) ($MN)
  • Table 127 Middle East & Africa Malaria Vaccine Market Outlook, By Agent (2021-2030) ($MN)
  • Table 128 Middle East & Africa Malaria Vaccine Market Outlook, By Anopheles Species (2021-2030) ($MN)
  • Table 129 Middle East & Africa Malaria Vaccine Market Outlook, By Plasmodium Vivax (2021-2030) ($MN)
  • Table 130 Middle East & Africa Malaria Vaccine Market Outlook, By Plasmodium Falciparum (2021-2030) ($MN)
  • Table 131 Middle East & Africa Malaria Vaccine Market Outlook, By Other Agents (2021-2030) ($MN)
  • Table 132 Middle East & Africa Malaria Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 133 Middle East & Africa Malaria Vaccine Market Outlook, By Pre-Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 134 Middle East & Africa Malaria Vaccine Market Outlook, By Erythrocytic Vaccine (2021-2030) ($MN)
  • Table 135 Middle East & Africa Malaria Vaccine Market Outlook, By Multi-antigen Vaccine (2021-2030) ($MN)
  • Table 136 Middle East & Africa Malaria Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 137 Middle East & Africa Malaria Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 138 Middle East & Africa Malaria Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 139 Middle East & Africa Malaria Vaccine Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 140 Middle East & Africa Malaria Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
  • Table 141 Middle East & Africa Malaria Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 142 Middle East & Africa Malaria Vaccine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 143 Middle East & Africa Malaria Vaccine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 144 Middle East & Africa Malaria Vaccine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 145 Middle East & Africa Malaria Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 146 Middle East & Africa Malaria Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 147 Middle East & Africa Malaria Vaccine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 148 Middle East & Africa Malaria Vaccine Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 149 Middle East & Africa Malaria Vaccine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 150 Middle East & Africa Malaria Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)